| Document |
Document Title |
|
WO/2019/170521A1 |
The present invention relates to a new intermediate for the synthesis of obeticholic acid, the compound of formula (I) or a geometric isomer thereof, a process for obtaining the same, as well as the use of said intermediate in the synthe...
|
|
WO/2019/159020A1 |
Disclosed is a process for producing cholesterol from fish oil, including the following steps: (a) distilling fish oil in a vacuum distillation column to obtain a first residue and a first distillate, (b) distilling the first distillate ...
|
|
WO/2019/155217A1 |
The invention relates to methods for disrupting cholesterol crystals and related methods for the prevention and/or treatment of disease.
|
|
WO/2019/129249A1 |
The present invention relates to a novel use of a triterpenoid. In particular, the present invention provides a use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutica...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/119832A1 |
Provided are a compound for treating metabolic diseases having the structure as shown in formula (I) or formula (II), or a racemate, stereoisomer, geometric isomer, tautomer, solvate, hydrate, metabolite, pharmaceutically acceptable salt...
|
|
WO/2019/106865A1 |
Provided are: an acyl novel steryl glucoside; and a method for producing an acyl steryl glucoside by using labyrinthula as a raw material. This acyl steryl glucoside is represented by structural formula (I), structural formula (II), or s...
|
|
WO/2019/108673A1 |
Cataract and presbyopia affect billions of people worldwide. Described herein are new compounds and methods of treating and preventing these diseases.
|
|
WO/2019/097434A1 |
The aspects of the present disclosure relates to novel lanosterol derivatives and novel 25-hydroxycholesterol derivatives including their pharmaceutically acceptable salts as well as methods of treatment and pharmaceutical compositions a...
|
|
WO/2019/085963A1 |
The present application belongs to the field of pharmaceutical chemistry, and relates to a method for preparing a cholic acid compound. Specifically, the present application provides a process for preparing a compound as shown in formula...
|
|
WO/2019/081586A1 |
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of...
|
|
WO/2019/078359A1 |
Provided is a method for producing a sterol. A sterol is produced by culturing a microorganism of the class Labyrinthulomycetes, which is capable of producing the sterol and has been modified so as to lower the activity of 24-dehydrochol...
|
|
WO/2019/057222A1 |
A slug extract and an effective component therein, the extract being obtained by performing supercritical CO2 extraction or organic solvent reflux extraction, saponification, extraction with an organic solvent and organic solvent recover...
|
|
WO/2019/053742A1 |
The present invention discloses solvent free process for extracting cholesterol free of impurities from milk fat. The so isolated cholesterol is useful for the further preparation of vitamin D3. The present invention further provides pha...
|
|
WO/2019/050430A1 |
The invention relates to the wood chemical industry and concerns a method for extracting phytosterols from tall oil pitch. The present method of extracting phytosterols from tall oil pitch involves saponifying tall oil pitch using an alk...
|
|
WO/2019/024920A1 |
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, ...
|
|
WO/2019/020067A1 |
The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and the relevant intermediates. In particular, the present invention relates to a method for...
|
|
WO/2019/021122A2 |
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune dis...
|
|
WO/2019/023103A1 |
The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.
|
|
WO/2019/015914A1 |
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) hydrogenation of the double bond and reductive opening of the epoxide of a compound of formula (II) or a salt or solvate t...
|
|
WO/2018/234540A1 |
The present invention relates to a cocrystal of beta-sitosterol or a pharmaceutically acceptable ester thereof or an edible acceptable ester thereof and an organic carboxylic acid coformer, an hydrate crystal form of beta-sitosterol havi...
|
|
WO/2018/227940A1 |
A method for preparing ursodeoxycholic acid via a chemical-enzymatic process, comprising: adding hyodeoxycholic acid to a first organic solvent, and oxidising under the effect of an oxidising agent to obtain 6-oxo-lithocholic acid; addin...
|
|
WO/2018/223836A1 |
The present invention relates to a novel crystal form of a compound (I), a method for preparing same, and an application. Crystal form CS3, crystal form CS2, crystal form CS5, and crystal form CS8 of the compound (I) provided by the pres...
|
|
WO/2018/226724A1 |
The present application relates to methods of treating or preventing an eye disease (e.g., a diabetic eye disease) in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the application.
|
|
WO/2018/221479A1 |
The purpose of the present invention is to provide a fluorescent substrate for a transporter, the fluorescent substrate maintaining high transport performance while being unlikely to be quenched and exhibiting strong fluorescent intensit...
|
|
WO/2018/218281A1 |
A process for inhibiting the formation of gas hydrates in a hydrocarbon fluid comprising adding to the hydrocarbon fluid, a gas hydrate anti-agglomerate which is a biodegradable anti-agglomerant derived from a naturally occurring substance.
|
|
WO/2018/220513A1 |
The invention relates to an improved process for the preparation of compound of formula (A), which is an intermediate in the preparation of Obeticholic acid or its analogous compounds thereof.
|
|
WO/2018/222701A1 |
The present application relates to methods of treating or preventing a renal disease, disorder, or condition (e.g., age-, diabetes- and/or obesity-related renal disease, disorder, or condition) in a subject in need thereof, comprising ad...
|
|
WO/2018/211413A1 |
The invention of the present application relates to crystalline forms of obeticholic acid and process for preparation thereof. Specifically, the invention of present application relates to crystalline forms VD1, VD2, VD3, VD4 and VD5 of ...
|
|
WO/2018/213055A1 |
Oxysterol-statin compounds and methods of synthesizing the same are provided for use in promoting osteogenesis, osteoinduction and/or osteoconduction. Methods of synthesizing in a single container OXY133-statin compounds having high yiel...
|
|
WO/2018/201516A1 |
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...
|
|
WO/2018/194253A1 |
A method for biological tissue transparency using an agent for biological tissue transparency containing CHAPS enables fast transparency without tissue degeneration.
|
|
WO/2018/194426A1 |
The present invention provides a method for preparing a bile acid derivative by using a continuous flow reaction. When a bile acid derivative is synthesized using a continuous flow reaction, according to the present invention, the reacti...
|
|
WO/2018/165269A2 |
The crystalline forms of obeticholic acid and methods of preparation and use thereof are described.
|
|
WO/2018/164715A1 |
The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.
|
|
WO/2018/146641A1 |
The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides ...
|
|
WO/2016/079519A9 |
The invention relates to compounds of formula (I) wherein R1, R2, Y1, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.
|
|
WO/2018/137683A1 |
Disclosed are a lanosterol prodrug compound, a pharmaceutically acceptable salt and an isomer thereof, and a pharmaceutical composition comprising the lanosterol prodrug compound and the use thereof in the preparation of a drug for treat...
|
|
WO/2018/135699A1 |
The present invention provides a novel ergostenol glycoside derivative. The ergostenol and the glycoside derivative thereof according to the present invention suppresses the production of chemokines increasing according to the skin infla...
|
|
WO/2018/085623A1 |
Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method...
|
|
WO/2018/075698A1 |
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are...
|
|
WO/2018/075699A1 |
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are con...
|
|
WO/2018/064755A1 |
A transfection reagent composition comprising: 30-60MOL% of an cationic lipid, or pharmaceutical acceptable salt thereof; 10-60 MOL% structural lipid; a sterol and 0.1 to about 10MOL% of a stabilizing agent is provided. The reagent is pa...
|
|
WO/2018/064649A1 |
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...
|
|
WO/2018/059241A1 |
Disclosed are an extract with a detoxification pharmaceutical effect and a preparation method therefor. An effective component of the extract has the following chemical structural characteristics: a cholestenol compound with hydroxyl (OH...
|
|
WO/2018/054300A1 |
Provided is a crystalline form cholic acid derivative free alkali, a preparation method therefor and an application. The chemical name of the cholic acid derivative free alkali is (5R)-5-((2R)-2-((3R,5S,6R,7R,10S,13R)-6-ethyl-3,7-dihydro...
|
|
WO/2018/050815A1 |
The present invention relates to a compound of formula (I), in which R' represents a -(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group com...
|
|
WO/2018/050814A1 |
The present invention relates to a compound of formula (I), in which R' represents a –(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group c...
|
|
WO/2018/026837A1 |
Compositions comprising oxygenated cholesterol sulfates (OCS) are provided. The OCS is, for example, 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or 5-cholesten, 3, 25-diol, disulfate (25HCDS). The compositions may be used to prevent and/o...
|
|
WO/2018/013613A1 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
